Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRTSNASDAQ:PRPHNASDAQ:UBXNASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTSGritstone bio$0.35$0.03▼$3.17$3.50M0.497.01 million shs61.02 million shsPRPHProPhase Labs$0.37+4.7%$0.33$0.22▼$4.53$14.54M-0.433.10 million shs3.62 million shsUBXUNITY Biotechnology$0.79+1.8%$0.86$0.66▼$3.10$13.36M1.05164,628 shs122,715 shsVYNEVYNE Therapeutics$0.94+2.4%$1.27$0.88▼$4.30$13.97M1.56127,293 shs152,697 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTSGritstone bio0.00%0.00%0.00%0.00%-95.85%PRPHProPhase Labs+4.69%+0.94%+14.29%-5.71%-91.86%UBXUNITY Biotechnology+1.83%-10.15%-2.34%-53.52%-39.22%VYNEVYNE Therapeutics+2.37%+2.02%-22.92%-44.02%-57.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRTSGritstone bioN/AN/AN/AN/AN/AN/AN/AN/APRPHProPhase Labs0.708 of 5 stars0.03.00.00.01.41.70.6UBXUNITY Biotechnology3.3746 of 5 stars3.32.00.04.70.00.80.6VYNEVYNE Therapeutics2.3458 of 5 stars3.53.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTSGritstone bio 2.50Moderate Buy$2.17∞ UpsidePRPHProPhase Labs 0.00N/AN/AN/AUBXUNITY Biotechnology 2.50Moderate Buy$3.75374.56% UpsideVYNEVYNE Therapeutics 3.00Buy$6.25564.61% UpsideCurrent Analyst Ratings BreakdownLatest GRTS, UBX, VYNE, and PRPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UBXUNITY BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.00 ➝ $2.005/16/2025UBXUNITY BiotechnologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$6.00 ➝ $1.004/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.504/23/2025UBXUNITY BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/23/2025UBXUNITY BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025UBXUNITY BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/24/2025UBXUNITY BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTSGritstone bio$496K0.00N/AN/A$0.54 per share0.00PRPHProPhase Labs$6.77M2.25N/AN/A$0.25 per share1.47UBXUNITY Biotechnology$240K56.66N/AN/A$0.39 per share2.03VYNEVYNE Therapeutics$500K28.61N/AN/A$3.53 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/APRPHProPhase Labs-$53.36M-$1.26N/AN/AN/A-217.64%-184.38%-64.59%8/13/2025 (Estimated)UBXUNITY Biotechnology-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%7/22/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)Latest GRTS, UBX, VYNE, and PRPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million4/22/2025Q1 2025UBXUNITY Biotechnology-$0.43-$0.43N/A-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRTSGritstone bioN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/AUBXUNITY BiotechnologyN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTSGritstone bio1.832.542.54PRPHProPhase Labs0.301.030.98UBXUNITY BiotechnologyN/A1.951.95VYNEVYNE TherapeuticsN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTSGritstone bio48.46%PRPHProPhase Labs9.45%UBXUNITY Biotechnology29.49%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipGRTSGritstone bio4.61%PRPHProPhase Labs20.70%UBXUNITY Biotechnology5.80%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRTSGritstone bio190108.57 million111.84 millionOptionablePRPHProPhase Labs13041.54 million32.94 millionOptionableUBXUNITY Biotechnology6017.21 million16.21 millionOptionableVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionableGRTS, UBX, VYNE, and PRPH HeadlinesRecent News About These CompaniesVYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 46.8% in MayJune 18 at 2:47 AM | americanbankingnews.comVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comVYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.April 27, 2025 | nasdaq.comVYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque PsoriasisApril 27, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)April 26, 2025 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25, 2025 | za.investing.comVyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque PsoriasisApril 25, 2025 | biospace.comFDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concernsApril 25, 2025 | fiercebiotech.comFDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25, 2025 | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)March 12, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)March 7, 2025 | markets.businessinsider.comVYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTS, UBX, VYNE, and PRPH Company DescriptionsGritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.ProPhase Labs NASDAQ:PRPH$0.37 +0.02 (+4.69%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.34 -0.02 (-5.84%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.UNITY Biotechnology NASDAQ:UBX$0.79 +0.01 (+1.83%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.04%) As of 06/18/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.VYNE Therapeutics NASDAQ:VYNE$0.94 +0.02 (+2.37%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.94 +0.00 (+0.49%) As of 06/18/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
